UCB:EBR
UCB SA
၂၀၃.၆၀ €
arrow_downward
-၀.၄၉%(-၁.၀၀) 1D
အောက် ၁၉, GMT+၂ ၁၀:၂၉:၃၄ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCB...
Open
၂၀၅.၅၀ €
High
၂၀၆.၄၀ €
Low
၂၀၃.၆၀ €
Mkt. cap
ဋေ ၃.၉၆ ထ
Avg. vol.
၂.၅၅ သိန်း
Volume
၁.၂၄ သောင်း
Dividend
၀.၅၀%
Quarterly dividend
၀.၂၅ €
Ex-dividend date
၂၀၂၆ မေ ၄
P/E ratio
၁၈.၀၁
52-wk high
၂၈၉.၅၀ €
52-wk low
၁၉၇.၄၅ €
EPS
၁၁.၃၁ €
Shares outstanding
၁၉.၄၅ ကုဋေ
No. of employees
၉ ထောင်
Open
၂၀၅.၅၀ €
High
၂၀၆.၄၀ €
Low
၂၀၃.၆၀ €
Mkt. cap
ဋေ ၃.၉၆ ထ
Avg. vol.
၂.၅၅ သိန်း
Volume
၁.၂၄ သောင်း
Dividend
၀.၅၀%
Quarterly dividend
၀.၂၅ €
Ex-dividend date
၂၀၂၆ မေ ၄
P/E ratio
၁၈.၀၁
52-wk high
၂၈၉.၅၀ €
52-wk low
၁၉၇.၄၅ €
EPS
၁၁.၃၁ €
Shares outstanding
၁၉.၄၅ ကုဋေ
No. of employees
၉ ထောင်
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ နာရီ
UCB wins FDA approval for ZILBRYSQ autoinjector. UCB stock carries EUR 39.0 billion market value
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၃ နာရီ
UCB stock pre-market at EUR 204.05: biopharma group overview
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၂ ရက်
Deutsche Bank keeps EUR 295.00 target for UCB stock
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA